Biocryst Pharmaceuticals Inc $10.44

down -0.49


22/9/2014 04:00 PM  |  NASDAQ : BCRX  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get BCRX Trend Analysis - it has outperformed the S&P 500 by 32%

Partner Headlines

  1. BioCryst Receives Additional NIAID Funding For Manufacture and Development ...

    Benzinga
  2. Momentum Stocks Showing Weakness

    Benzinga
  3. BioCryst Announces RAPIVAB Trial Results For The Treatment Of Influenza ...

    Benzinga
  4. BioCryst Pharmaceuticals, Inc. Sinks; WHO Notes Ebola Safety Data Unavailable

    Benzinga
  5. BioCryst To Present Peramivir Trial Results For The Treatment Of Influenza ...

    Benzinga
  6. US Stock Futures Gain Ahead Of Consumer Data

    Benzinga
  7. Biotechs That Might Benefit From Ebola

    Benzinga
  8. Benzinga's Top #PreMarket Gainers

    Benzinga
  9. Stocks Hitting 52-Week Highs

    Benzinga
  10. Benzinga's Top Initiations

    Benzinga
  11. JP Morgan Initiates BioCryst Pharmaceuticals At Overweight

    Benzinga
  12. MLV & Co Sees Positive Momentum Going Into 2H14 For BioCryst Pharmaceuticals

    Benzinga
  13. Ebola Stocks Continue Higher

    Benzinga
  14. UPDATE: Wells Fargo Upgrades BioCryst

    Benzinga
  15. UPDATE: H.C. Wainwright & Co. Initiates Coverage on BioCryst Pharmaceuticals ...

    Benzinga
  16. Benzinga's Top Initiations

    Benzinga
  17. Morning Movers for Feb. 25, 2014: IMUC, MSO, ZU, CARA, VSI, TSLA, XOMA, ...

    Benzinga
  18. Benzinga's Top #PreMarket Gainers

    Benzinga
  19. Benzinga's Top Downgrades

    Benzinga
  20. Benzinga's Top Initiations

    Benzinga
  21. UPDATE: JMP Securities Places BioCryst Pharmaceuticals PT Under Review, ...

    Benzinga
  22. US Stock Futures Gain Ahead Of GDP Data

    Benzinga
  23. BioCryst Files Peramivir NDA for Influenza

    Benzinga
  24. Benzinga's Top #PreMarket Gainers

    Benzinga
  25. BioCryst Selects Two Plasma Kallikrein Inhibitors for Hereditary Angioedema ...

    Benzinga
  26. BioCryst Initiates Phase 2a Clinical Trial of BCX4161 in Patients with ...

    Benzinga
  27. Benzinga's Top Pre-Market Gainers

    Benzinga
  28. BioCryst Awarded Up to $22M Contract by the NIAID to Develop BCX4430 for ...

    Benzinga
  29. JMP Calls BioCryst's Oral Kallikrein 'Potential Game Changer,' Believes ...

    Benzinga
  30. UPDATE: JMP Securities Raises PT on BioCryst Pharmaceuticals on Potential ...

    Benzinga
  31. Benzinga's Top Pre-Market Gainers

    Benzinga
  32. FDA Removes Clinical Hold on BioCryst's BCX 4161 -8K

    Benzinga
  33. Benzinga's Top Pre-Market Gainers

    Benzinga
  34. BioCryst Prices 4M Share Offering at $4.40/Share

    Benzinga
  35. UPDATE: Bank of America Downgrades BioCryst Pharmaceuticals on Valuation

    Benzinga
  36. Benzinga's Top Pre-Market Losers

    Benzinga
  37. UPDATE: Bank of America Resumes Coverage on BioCryst Pharmaceuticals with ...

    Benzinga
  38. Benzinga's Small Cap Movers for Wednesday January 2, 2013

    Benzinga
  39. Ballots Are In: Worst CEO in the Biotech Industry Is . . .

    YCharts
  40. BioCryst Pharmaceuticals, Presidio Pharmaceuticals Terminate Merger Agreement

    Benzinga
  41. BioCryst Broad-Spectrum Antiviral BCX4430 Shows Effective and Well Tolerated ...

    Benzinga
  42. BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  43. BioCryst Announces Withdrawal of BCX5191 Investigational New Drug Application ...

    Benzinga
  44. Benzinga's M&A Chatter for Thursday October 18, 2012

    Benzinga
  45. BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge

    Benzinga
  46. BioCryst Pharmaceuticals, Presidio Pharmaceuticals to Merge

    Benzinga
  47. BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  48. A Peek Into The Market Before The Trading Starts

    Benzinga
  49. IHS, Ebix Included in Stocks Up on High Volume Friday

    FoxBusiness
  50. Swine Flu Has BioPharma as Happy as Pigs in Filth

    Benzinga
Trading Center